Enzandro 160 mg (Enzalutamide)
| Active Ingredient (Generic Name): | Enzalutamide |
| Manufacturer: | Abbott Healthcare Private Limited |
| Packaging: | 7 tablets in 1 strip |
| Strength: | 160 MG |
| Delivery Time: | 6 To 15 days |
| SKU: | Enzandro 160 mg (Enzalutamide) |
Product details
| Quantity |
28 Tablet/s ,56 Tablet/s ,84 Tablet/s |
|---|
Description
Enzalutamide is a medication used in the treatment of prostate cancer.
Customer Reviews
Related Products
Anastrozole 1 mg
Price range: $75.00 through $510.00
Select options
This product has multiple variants. The options may be chosen on the product page
Rifagut 200 mg (Rifaximin)
Price range: $93.00 through $168.00
Select options
This product has multiple variants. The options may be chosen on the product page
Anastrozole 1 mg
Price range: $75.00 through $510.00
Select options
This product has multiple variants. The options may be chosen on the product page
Flutamide 250 mg
Price range: $75.00 through $180.00
Select options
This product has multiple variants. The options may be chosen on the product page
Leuprolide Acetate 1 mg
Price range: $90.00 through $240.00
Select options
This product has multiple variants. The options may be chosen on the product page
Imatinib 400 mg
Price range: $75.00 through $207.00
Select options
This product has multiple variants. The options may be chosen on the product page
Azacitidine 100 mg Injection
Price range: $250.00 through $690.00
Select options
This product has multiple variants. The options may be chosen on the product page
Cabozantinib 20 mg
Price range: $120.00 through $342.00
Select options
This product has multiple variants. The options may be chosen on the product page
Capecitabine 500 mg
Price range: $80.00 through $228.00
Select options
This product has multiple variants. The options may be chosen on the product page
Gemcitabine 200 mg Injection
Price range: $35.00 through $99.00
Select options
This product has multiple variants. The options may be chosen on the product page
Reviews
Clear filtersThere are no reviews yet.